Convatec Group Plc · LSE:CTEC
Convatec — Investor Day (April 2026)
101 slides from Convatec's investor day presentation, April 2026
Slide 1: Accelerate CMD2026
convatec Accelerate CMD2026
Slide 2: Important notice
For the purposes of this notice, “Presentation” means this document, its contents or any part of it, any oral presentation, any question or answer session and any written or oral material discussed or distributed before, during or after the Presentation meeting. This information, which does not purp
Slide 3: Pioneering trusted medical solutions to improve the lives we touch
Pioneering trusted medical solutions to improve the lives we touch
Slide 4: Welcome
Welcome Jonny Mason Chief Executive Officer Y convatec CMD2026
Slide 5: Agenda
Strategic evolution Jonny Mason 14:00 – 14:30 Category breakout sessions (in rotation) 14:35 – 16:05 Advanced Wound Care Tanja Dormels Group 1 Ostomy Care Bruno Pinheiro Group 2 Continence Care Mark Jassey Group 3 Infusion Care Kjersti Grimsrud Group 4 Accelerate pioneering innovation Divakar Ramakr
Slide 6: Leadership and organisation structure
Chief Executive Officer Chief Financial Officer Chief People Officer Chief Strategy & Chief Science, Innovation Development Officer & Quality Officer Advanced Wound Ostomy Care Continence Care & Infusion Care Chief Commercial Care HSG Officer 6
Slide 7: We are now ready to accelerate
We are now ready to accelerate 7
Slide 8: Four categories and market sizes
Advanced Wound Ostomy Care Continence Care Infusion Care Care (AWC) (OC) (CC) (IC) $6.0bn1 $3.7bn1 $2.4bn1 c.$1bn1 MSD market growth MSD market growth MSD market growth HSD market growth 1: Convatec-estimated global market size and growth rates 8
Slide 9: Ageing populations and chronic conditions
Increasing life expectancy Chronic conditions are People living longer with and ageing populations increasing chronic conditions Global population aged 65+ The prevalence of chronic Survival with chronic 2060 1.9bn conditions continues to grow conditions improved in approximately 1 in 3 2024 0.8bn A
Slide 10: Deep expertise created and shared across Convatec
Skin contact, Patient support, Design for care and repair Clinical evidence Home Services manufacturing Adhesives / HCP education Group, me+, & quality polymers Convatec clinics Deep expertise is created and shared across Convatec 10
Slide 11: Delivering value for all our customers
Delivering value for all our customers Patients Professionals Payers - Solving medical needs - Clinical effectiveness - Health economics - Leading products - Reliable product availability - Reduced system costs - Education and training - Better medical outcomes - Outstanding service
Slide 12: FISBE has made us stronger
FISBE has made us stronger &) convatec CMD2026
Slide 13: FISBE 1.0 and 2.0 phases
2016-19 2020-22 2023-25 FISBE 2.0 Deliver the pivot FISBE 1.0 • Wave 1 launches Foundations in place • 5-7% organic growth • Focus & Simplify • Margin expansion Post-IPO • Build the team • EPS1 and cash growth • Double R&D spend • No growth • Increase capex • Inconsistent delivery • Low innovation 1
Slide 14: FISBE has made us stronger
FISBE has made us * Four focused, global categories with k *« Global R&D to drive innovation; strony « Global operations to drive produ functional sy * Centres of Excellence in market acce pricing, marketir * Convatec Business Services driv effectiveness of corpors « Strong team: high engagement, lo
Slide 15: Dynamic environment and diversified growth
Dynamic • Reimbursement dynamics are a feature of MedTech environment • We account for this in our planning and guidance Significantly • Investment in new expertise delivers market coverage and value: strengthened market access & reimbursement, clinical evidence & health economics expertise Demonstr
Slide 16: Revenue, margin, EPS and free cash flow 2021-2025
Revenue ($m) and organic revenue growth1 Operating profit margin3 Excl. InnovaMatrix® shown in italics2 6.4% 6.8% 4.8% 22.3% 7.7% 2,439 5.9% 21.2% 7.2% 2,289 20.2% 5.6% 19.5% 5.3% 2,142 2,038 2,073 17.7% 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 Diluted earnings per share3 Free cash flow to
Slide 17: Business is stronger; demand is growing
• Team capabilities have been built Business is • FISBE turnaround has started to deliver strong cash returns stronger • Focused operating model is working • Structurally growing markets Demand is • Increase in ageing populations, higher instances of chronic disease growing • Improving therapies and
Slide 18: Our new strategy is Accelerate
Our new strategy is Accelerate ©) convatec CMD2026
Slide 19: Accelerate: realising our full potential
2016-19 2020-22 2023-25 Accelerate Realising our full potential FISBE 2.0 • Scale up Wave 1 Deliver the pivot • Launch Waves 2, then 3 FISBE 1.0 • Increase growth capex Foundations in place • 6-8% organic revenue growth • 24-26% operating margin1 Post-IPO • Strong cashflow to support growth • Sustai
Slide 20: Accelerating sustainable and profitable growth
Accelerate CTEC Accelerating sustainable and profitable growth 20
Slide 21: Patients, healthcare professionals, payers and partners
Patients, healthcare professionals, payers and business partners • Support more people living with chronic conditions • Grow sales and increase segment share • Enhance customer loyalty, educate medical professionals, support patients • Invest in fastest growing segments, including by external innova
Slide 22: Products and services; digital and AI
Products and services, solving patient needs; leveraging digital & AI • Launch products and services to address existing and unmet patient needs • Generate and leverage clinical evidence • Deploy modern, standardised digital tools to drive productivity • Implement AI applications across key domains
Slide 23: Deliver right first time, at speed and with quality
Deliver right first time, on-time on-budget, at speed and with quality • Faster innovation cycle time • Focused commercial execution • Further simplification and productivity • Deliver high quality and responsible business goals 23
Slide 24: Perform as one team
Perform as one team, with smooth hand-offs, learn as we grow • Purpose-led, performance-driven leaders and teams • Strong engagement, built around effective teamwork • Best-in-class leadership and capabilities • Living our values and forever caring promise 24
Slide 25: All four categories will Accelerate
All four categories will Accelerate 25
Slide 26: Advanced Wound Care
Advanced Wound Care Customer • Scale five major launches, focusing on deepening customer loyalty focused growth • Create and grow an exciting new market segment with ConvaNiox Technology • New clinical evidence generation – RCTs in ConvaNiox, InnovaMatrix & Innovation • Develop new indications to ad
Slide 27: Ostomy Care
Ostomy Care • Grow across the continuum of care Customer • Expand access in acute / post acute via GPO wins & HCP engagement focused growth • Drive community sales leveraging me+ and Home Services Group Technology • Expand the portfolio with Natura Body & Innovation • Advance adhesive innovation to
Slide 28: Continence Care
Continence Care Customer • Lead with further outstanding US service US; expand service model OUS focused growth • Strengthen portfolio with GentleCath Air Pocket & Set Technology • Innovate to improve user protection and reduce UTI risk & Innovation • Strengthen differentiation versus competition th
Slide 29: Infusion Care
Infusion Care Customer • Partner with customers driving infusion adoption to expand market focused growth • Diversify customers and therapies to reinforce leadership Technology • Innovate alongside fast evolving pump and monitoring technologies & Innovation • Expand into high-dose biologics Executio
Slide 30: Launch Waves 1, 2 and 3
Wave 1 Wave 2 Wave 3 2022-25 2026-27 2028+ • InnovaMatrix • ConvaNiox ConvaFoam with antimicrobial AWC • 780G MioAdvance Extended Wear • Flexi-Seal Air Next generation ConvaNiox • ConvaFoam • ConvaFiber Adhesives to reduce • Infusion sets for Beta Bionics iLet • ConvaVAC OC peristomal skin • AbbVie
Slide 31: Medium term targets
Medium term organic revenue target Medium term targets Prior New Advanced Wound Care M/HSD HSD1 6-8% organic revenue growth Ostomy Care MSD M/HSD 24-26% operating margin Continence Care MSD M/HSD DD EPS growth (per annum) Infusion Care HSD DD DD FCFE growth (CAGR) 1: AWC growth guide in 2027 is M/HS
Slide 32: Category presenters
Advanced Wound Care Ostomy Care Continence Care Infusion Care presenters Convatec Guests 32
Slide 33: President Advanced Wound Care
President Advanced Wound Care
Slide 34: Hard-to-heal wounds: 100m patients worldwide
Structural growth driver Hard-to-heal wounds 100m patients worldwide 34
Slide 35: Market segments grow MSD
Biologics Market segments grow MSD $8.0bn suNPWT devices 6% 1.3 Biologics $6.0bn 5% 0.9 Biologics Foams suNPWT devices 1.0 13% 0.5 Foams 3.1 6% Antimicrobials + Fiber Antimicrobials + Fibers 2.3 Other dressings 1.6 Antimicrobials & 1.3 5% Fibers Other dressings 0.9 4% 1.1 2025 2030 Source: SmartTrak
Slide 36: AWC revenue and organic growth
• Sustained leadership in Antimicrobials; broadened portfolio into complementary market segments • AWC accelerated from no growth to MSD (ex-InnovaMatrix) 743 753 695 +4.3% +4.1% +5.7% 621 592 +6.8% 547 +9.2% -2.7% 2020 2021 2022 2023 2024 2025 Organic revenue growth ex-InnovaMatrix shown in italics
Slide 37: Increasing product differentiation and raising standard of care
Increasing product differentiation and raising standard of care ConvaFiber ConvaFoam ConvaVAC InnovaMatrix ConvaNiox • Significant non- • Scaling-up • Launched in • Highly effective • Ground-breaking silver platform globally Europe in H1 26 skin substitute platform for hard- upgrade to-heal wounds O
Slide 38: Global Foam share increased to c.6%
Our global Foam share has increased to c.6%; initial target 10% +1ppts share adds 3% to AWC growth & 1% to Group growth 3 2 1 Clinical evidence driving HCP adoption for pressure Multi-layer competitive injury treatment; largest differentiation including addressable patient pool Aquacel brand drives
Slide 39: ConvaNiox
ConvaNioxTM 60% more ulcers healed 3x faster wound area reduction within 12 weeks treatment in diabetic foot ulcers 40% 100 ConvaNiox “A very good product, beyond 90 expectations, especially 35% 80 considering the underlying 30% pathology; very well appreciated Percentage area reduction 70 by patien
Slide 40: Scaling up our pipeline of innovative new products
Scaling up our rich pipeline of innovative new products High single digit InnovaMatrix ConvaVAC Disciplined execution, further deepening Mid single digit ConvaNiox ConvaFiber customer relationship and loyalty ConvaFoam Base business Creating an exciting new segment with our ground-breaking ConvaNiox
Slide 41: President Ostomy Care
Ostomy Care Bruno Pinheiro President Ostomy Care © convatec CMD2026
Slide 42: Leading positions in growing markets
Convatec has leading positions in growing markets +4% 1.1 RoW +6% 0.8 0.9 +3% 0.8 North America prevalence of 2 piece +4% 2.6 2.1 Europe prevalence of 1 piece 2025 2030 Source: Convatec 42
Slide 43: Ostomy Care growth accelerated
our ways of selling and working, focusing our portfolio and integration with Home Services Group • Growth has accelerated, while executing portfolio focus, driven by clinical evidence based selling and new products Flexi seal strong growth due to Covid related Portfolio $676m hospitalisations; norma
Slide 44: From hospital to home through the continuum of care
From hospital to home: winning strategy through the continuum of care Strategy is delivering 1 2 3 1: Group Purchasing Organisation 44
Slide 45: Body line and Plus line portfolio
Plus line Body line Skin barriers Body skin barriers Yet to launch Natura Body 2-piece Natura 2-piece Esteem 1-piece Esteem Body 1-piece Accessories 45
Slide 46: Pivoting to the fastest growing sectors
Pivoting to the fastest growing sectors Investing in fastest growing segments $4.6bn +7% $3.7bn Accessories +10% BODY line Soft convex Premium launches products +3% Rigid products PLUS line existing products +1% Flat products 2025 2030 Source: Convatec 46
Slide 47: Esteem Body market share gain and launches
High single-digit market share gain in 2 years Launched in 20 markets 1 2 93%1 of HCPs & 95%1 of patients report high comfort, confidence and wear performance 3 4 1: source: IQVIA, August 2025–n= 930 HCPs across Germany, the U.S., Italy, Australia, and Japan, n= 1,008 consumers 47
Slide 48: Continuum of care: pre-acute, post-acute, community
From hospital to home: winning strategy through the continuum of care Pre Acute Post-acute Community Support HCPs & new patients me+ programme supports Simplifying access to tailored pre- and post-operative recovery and wellbeing Ostomy solutions HCP engagement; new acute starts Consumer support & r
Slide 49: Ostomy Care growth outlook
Further leverage our innovative, expanding portfolio Mid-high single digit Mid Support HCPs and patients across the single digit full continuum of care Elevate the standard of care with 2020-2025 2027+ clinically-led execution 49
Slide 50: President Continence Care & Home Services Group
President Continence Care & Home Services Group
Slide 51: Intermittent catheter market size and growth
Intermittent catheter market size and growth +4% 0.4 +6% 0.3 RoW +4% 1.0 0.8 US +4% Europe 1.5 1.3 2025 2030 Source: Convatec 51
Slide 52: Continence Care revenue growth
537 501 +6.6% +8.3% 457 426 +6.5% 405 +5.1% 363 +3.4% +5.4% 2020 2021 2022 2023 2024 2025 CAGR calculated from 2021 to normalise for Cure acquisition 52
Slide 53: Home Services Group platform
Prescription NPS > World-class Insurance Proprietary Trustpilot + software = #1 Medical platform Supply Store on Trustpilot Supplies Retention Trusted by patients 53
Slide 54: Improvements 2022 to 2025
2022 2025 2022 2025 2022 2025 40% 45% 23% 28% 54% 59% 54
Slide 55: Cure and GentleCath portfolio
Strong scientific Strong US brand, Premium performance – Value offer - Cure broad, accessible portfolio delivering dependable GentleCath hydrophilic with FeelClean up to 53% less quality Technology urethral damage1 Cure GentleCath GentleCath Air GentleCath Air Cure Aqua Cure Ultra closed systems Gli
Slide 56: Market dynamics in US and key European markets
Market dynamics (US & key European markets) +3% Compact 1.1 +7% Preferred in 0.8 European market +3% 0.2 Closed system 0.2 Standard Preferred in 0.9 +1% 0.9 US market Uncoated 0.3 +1% 0.4 2025 2030 Source: Convatec 56
Slide 57: Evidence, HCP engagement and direct to users
Prove the difference: Evidence Build clinical credibility for GentleCath with FeelClean Technology Show the difference: HCP Empower HCPs to champion GentleCath with engagement FeelClean Technology Bring the difference to life: Direct to users Make the science real by connecting evidence to everyday
Slide 58: Continence Care growth outlook
Drive further growth in US with world- class service from 180 Medical Mid-high single digit RoW Mid single digit Europe Leverage our product portfolio, including US innovative launches Execution excellence - implement our proven service model in US & globally 2020-2025 2027+ 58
Slide 59: President Infusion Care
Infusion Care Kjersti Grimsrud President Infusion Care Y convatec CMD2026
Slide 60: Increased insulin pump penetration opportunity
Pumps 7% CAGR ‘25-’30 People with Users of intensive Increased insulin pump diabetes insulin treatment Multiple 11% daily 93% penetration opportunity c.370m c.10% (37m) injection 0% Pump penetration (%) Durable CAGR ‘20-’25 ‘25-’30 6.7 7.0 pumps (%) 5.9 6.2 Innovation driving 4.5 4.9 5.4 7% 8% 3.9 4
Slide 61: Infusion Care revenue growth 2019-2025
• Pump penetration, our innovation and customer diversification drove strong growth 2021-25 (c.10% CAGR) • Supporting customers with new therapies and new form factors. Non-diabetes c.15% of IC revenue in 2025 (2024: 10%) $473m +12.5% $411m +11.2% $371m $341m +8.7% $316m +9.2% +11.5% $283m +18.5% $2
Slide 62: Innovative market leader diversifying customers and therapies
1 Innovative market leader 2 Diversifying customers and therapies 3 Investing to grow 62
Slide 63: Components of our modular platform
Components of our modular platform 1 Inserter Canula 2 4 Tubing Adhesive technology 3 63
Slide 64: Growing pump adoption has driven new innovations
Growing pump adoption and patient preference has driven new innovations 64
Slide 65: Delivery options: key benefits and limitations
• Strong clinical outcomes • Discrete, phone-managed • Discrete, phone-managed • Very easy to use Key • Ability to disconnect • Ability to disconnect • Ability to disconnect • Discrete, phone-managed benefits • Insulin capacity • Choice of infusion sets • No risk of tube tangling • No risk of tube t
Slide 66: Infusion Care growth outlook
Rising customer demand with pump and CGM1 innovation DD HSD Expand within diabetes; fast growth in Parkinsons disease Diversify customers and therapies 2020-2025 2027+ 1) Continuous Glucose Monitors 66
Slide 67: Chief Science, Innovation & Quality Officer
Chief Science, Innovation & Quality Officer 67
Slide 68: People, single use products and scientific depth
People Single use products Scientific depth Solutions = • User centred design • Design for high volume • Skin-material interfaces products + • Design for high quality • Tissue repair & healing digital + service • Infection prevention We create and leverage significant knowledge across our four chron
Slide 69: R&D investment and clinical evidence progress
1 2 3 4 – 2 x R&D / sales – Clinical evidence – 33 clinical trials – 8 in last 3 years percentage1 – Reimbursement – 20 publications – 8 in next 2 years – Broadened – Regulatory – 35 patents filed – Achieved 30% new leadership bench – Design for manufacture product vitality with deep expertise – Use
Slide 70: Clinical evidence: Aquacel Ag+ RCT results
Clinical evidence Case study: Aquacel AG+ RCT results • Aquacel Ag+ 74.8% 55.6% 56 days Standard of care Aquacel Ag+ Note: Complete wound closure is defined as 100% wound surface epithelialization Beraldo et al. J Wound Care. 2025 Mar 2;34(3):170-178. 1. RCT: Randomised Controlled Trial with 203 pat
Slide 71: Launch timeline by category
2022-2024 2025 2026 2027 InnovaMatrix US Outside US 780G MioAdvance Extended Wear Globally ConvaFoam US Europe Global Emerging Markets Infusion set for Beta Bionics iLet pump US AbbVie Parkinson’s Japan Europe US GentleCath Air for Women Europe & US Global Emerging Markets Infusion set for Tandem Mo
Slide 72: Portfolio positioning by category
Advanced Wound Care Continence Care Compact Standard Foam Ready to Use Antimicrobial + Fibers Biologics segment Premium suNPWT NO-Powered Multimodal Platform Value Infusion Care Ostomy Care Soft Flat/Rigid Convex Inset Platform Inset & Neria Inset Guard Guard Platforms Platform Diabetes Diabetes Non
Slide 73: Portfolio positioning by category
Advanced Wound Care Continence Care Compact Standard Foam Ready to Use Antimicrobial + Fibers Biologics segment Premium suNPWT NO-Powered Multimodal Platform Value Infusion Care Ostomy Care Soft Flat/Rigid Convex Inset Platform Inset & Neria Guard Platforms 1 Piece 2 Piece Accessories 73
Slide 74: Internal innovation programmes and business impact
Our strategy Example internal innovation programmmes Business impact Advancing our flagship ConvaFoam platform with proprietary Maximise AWC antimicrobial science functionality Sustain Next generation ConvaNiox internal accelerated manufacturing growth Adhesives and accessories which leverage our go
Slide 75: Faster cycle time and launch cadence
Faster cycle time Wave 2 will launch c.30% faster than Wave 1 Accelerating launch cadence Wave 2 : 8 launches in 2 years Wave 1 : 8 launches in 3 years Rapid clinical evidence generation >30 active studies today 75
Slide 76: Innovation approach and R&D metrics
• Unmet-need discovery and user-centered design • Platform-driven architectures grounded in scalable manufacturing and science • High-quality clinical evidence enabling regulatory approvals, market access and reimbursement • Operational discipline that accelerates and de-risks execution c.5% c.30% c
Slide 77: Accelerate Financial Performance
Accelerate Financial Performance Fiona Ryder Chief Financial Officer
Slide 78: Drivers of growth and returns
1 2 3 • Volume demand • R&D and commercial • High return growth capex investment • Execution excellence • Attractive bolt-on M&A • Disciplined P&L management • Winning products • Additional returns to • Productivity and simplification shareholders 78
Slide 79: Group revenue and organic growth by category
$2,439m $2,289m 6.4%1 $2,142m $2,038m $2,073m 6.8%1 Group $1,894m 6.0%1 12.5% revenue $1,827m 5.3% 5.6% 11.2% 2.3% 4.2% 8.7% 11.5% 9.2% IC 2.2% 18.5% 6.6% 8.3% 3.4% 6.5% 5.4% 5.4% 5.1% CC 4.5% 2.0% 4.2% 5.3% OC 1.0% 4.5% 1.7% 9.2% 6.8% 5.7%1 4.2%1 4.1%1 AWC 0.5% (2.7%) 2019 2020 2021 2022 2023 2024
Slide 80: +460 bps adjusted operating profit margin 2021-25
2021-25: +460 bps adjusted operating profit margin1 22.3% 21.2% 20.2% 19.5% 17.7% 2021 2022 2023 2024 2025 1. Adjusted operating margin 80
Slide 81: Operational capabilities and further opportunity
Operational Group capabilities Further opportunity 81
Slide 82: Progress since 2019 and momentum
Low Limited 2019 2.3% 19.4% c.$50m No growth and ageing product portfolio 5 consecutive years 4th year increase Increased 2x to DD EPS growth 2025 of 5-7% organic 22.3% >$100m pa Investment grade revenue growth +460bps last 4 years Share buybacks Outgrowing chronic Strongest-ever Positive Tracking t
Slide 83: We are now ready to Accelerate
We are now ready to Accelerate ae products Focused as aac meee commercial nial markets Proving growth & convatec CMD2026
Slide 84: Reinvestment drives future growth
6-8% growth Reinvestment drives drives future operational growth leverage Mid-20s operating margin1 target Reinvestment areas Research & Marketing & Clinical evidence Launching Development Sales generation products 1. Adjusted 84
Slide 85: COGS, hedging and P&L sensitivity
COGS Significant hedging P&L sensitivity 85
Slide 86: Capital allocation
Accelerate 1 2 3 4 Invest & build Grow dividends Invest in M&A Share buyback 300 4 Share buyback: $300m in 2025 3 M&A: over $500m cumulative since 2021 173 179 25 85 Dividend: growing in line x with earnings 112 140 2 88 111 130 86 64 121 1 Growth capex: 4x since 2021 with improving ROCE 32 55 59 62
Slide 87: 2025-26 growth capex investment accretive to ROCE
Capex 2025/26 capex investment areas Capacity for Inset & Neria Guard c.50% (underwritten by long-term contracts) IC CC Capacity for GC Air Pocket and Set c.10% (following success of GC Air for Women) c.20% Capacity for Natura Body OC (following the success of Esteem Body) Additional capacity for Co
Slide 88: ROCE and invested capital
5000 14% 4500 ROCE1 12% 4000 11% 11% 11% 10% 3500 3000 335 322 322 282 280 310 437 488 2500 337 359 384 588 2000 914 930 871 732 1047 947 1500 1000 1127 1190 1262 1295 1320 1081 500 0 2020 2021 2022 2023 2024 2025 Working Capital PPE & capitalised leases Other intangibles Goodwill 1. Group adjusted
Slide 89: Cash generation supports faster EPS growth
Cash generation supports faster EPS growth Operating profit growth 0) 100% cash conversion “O| Bolt-on M&A or further share buybacks “O| Stable finance & tax costs —O & convatec CMD2026
Slide 90: Medium-term targets
Mid term Rea targets Reinvestment Medium-term & guide returns • 6-8% organic revenue growth • Mid 20s operating margin • Double-digit EPS and DD FCFE CAGR 90
Slide 91: Realising our full potential
Realising our full potential Jonny Mason Chief Executive Officer Y convatec CMD2026
Slide 92: Accelerate: medium term target 6-8%
Medium term target 6-8% Accelerate 92
Slide 93: Pioneering innovation priorities
• Large, scalable • Strengthen • Deliver key trials • Secure value innovation engine processes reflecting • Expand generation contribution to • Substantial • Demand the of clinical evidence users and health investment in highest standards care systems developing new products 93
Slide 94: Execution excellence priorities
• Complete • Deploy modern, • Improve positions in • Building stronger automation journey standardised digital focus areas culture and top tools talent • Expand capacity • Disciplined • Vigilance on cyber bolt-ons • Purpose-led, • Execution security performance- excellence and • New technologies dri
Slide 95: Performing as one Convatec team
Culture Performing Metrics as one Convatec team 95
Slide 96: Flywheel of investment and growth
Structurally growing markets Driving Leading sustainable market value for 6-8% positions shareholders organic revenue Building growth and Recurring stronger revenue double-digit business for consumable customers EPS products Flywheel of New products investment & are working; growth strongest ever is
Slide 97: We are now ready to accelerate
We are now ready to accelerate 97
Slide 98: &
& 98
Slide 99: Jonny Mason, CEO and Fiona Ryder, CFO
Jonny Mason CEO Jonny was appointed Chief Executive Officer on 6 November 2025, following a period as Interim CEO, and joined Convatec as Chief Financial Officer in January 2022. Jonny has played an instrumental role in leading the company’s pivot to sustainable and profitable growth and shaping its
Slide 100: Bruno Pinheiro and Mark Jassey
Bruno Pinheiro President, Ostomy Care Appointed to CELT: 2021 Bruno was appointed as President, Ostomy Care, in May 2022. Bruno worked for Bristol Myers Squibb before the company sold Convatec in 2008. Bruno’s diverse experience spans across Sales, Business Development & Global Emerging Markets. Pri
Slide 101: James Kerton and Evelyn Douglas
James Kerton General Counsel & Company Secretary Appointed to CELT: 2024 James rejoined Convatec in May 2024 as General Counsel and Company Secretary, having previously held the role of VP, Deputy General Counsel from 2021 to 2022. James was previously General Counsel and Company Secretary at Zigup